Jeff Hansen
| This email address is being protected from spambots. You need JavaScript enabled to view it.
Successful Phase III trials at UAB contributed to the development of a novel “corrector-potentiator” combination drug therapy for cystic fibrosis patients.
These scientifically diverse researchers deliver lectures at American Society for Microbiology Branch meetings throughout the United States.
A UAB symposium on cardiovascular tissue engineering brought together some of the best in the business in this rapidly developing field of translational medicine.
The first target for the UAB spinoff Incysus Ltd. will be glioblastoma. Incysus has just received a European patent for its innovative approach to fighting cancer.
Knowledge from this study and others may help physicians boost healing and prevent heart failure in patients after a heart attack.
Mitochondrial DNA moving to the nucleus contributes to genomic instability in cancer cells, and a novel Fiber-FISH technique can rapidly map the mitochondrial DNA insertions in nuclear genomes.
These microcarriers may offer an entirely different approach to treating solid human tumors of numerous pathologic subtypes by delivering their encapsulated drug cargo to a tumor and protecting against collateral tissue damage.
UAB assays enabled the first genomewide association study of IgA1 O-glycosylation aberrancy in IgA nephropathy, a disease that frequently causes kidney failure.
Failure of hormone deprivation therapy used to slow prostate cancer in patients leads to castration-resistant prostate cancer, a lethal form of advanced disease with limited treatment options. Endostatin, used in combination therapy, may help delay onset of castration-resistant disease.
The findings suggest targeting specific T-cell subsets may be a therapeutic approach to prevent heart failure after a heart attack.